• Developing the next generation of nanomedicines

  • Developing the next generation of nanomedicines

  • Developing the next generation of nanomedicines

123

Cristal Therapeutics is a clinical stage pharmaceutical company developing targeted nanomedicines with superior therapeutic profiles for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential.

Read more

Oncology pipeline

Our in house programs are in oncology, and we are advancing our lead candidate, CPC634, through a Phase 2 clinical trials in patients with ovarian cancer. We are also progressing CPC879, an innovative oligonucleotide based therapeutic into preclinical studies.

Read more

CriPec®-based therapeutics

CriPec®-based therapeutics are new drug modality that is designed and engineered to either passively or specifically target defined cells or tissue in the body. They concentrate a drug payload and extend local exposure at the disease site while minimizing adverse effects on healthy tissues.

Read more

CriPec® technology platform

Our proprietary polymeric technology platform, CriPec®, enables the rational design and straightforward manufacturing of custom-made nanomedicines. It can be applied to innovative development candidates and in-market drugs to create novel nanomedicines.

Read more

Partnering

We have established several industry partnerships to co-create CriPec®-based therapeutics and assess their applicability in a number of therapeutic areas, including oncology and inflammation.

We are actively seeking partnerships for our proprietary inflammation programs.

Read more

Leadership team

We have an experienced management team of entrepreneurial life science executives who bring a powerful combination of leadership, scientific, technical, and clinical expertise.

Read more

Watch Informa interview with our CEO/CMO, Dr Axel Mescheder at BIOEurope 2018

Latest News

View all news

Events

Meet us at events